Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. Disc is building a portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology. The company is committed to developing treatments that empower and bring new opportunities to the many patients who suffer from hematologic diseases. Disc closed a reverse merger with Gemini Therapeutics on December 29, 2022 and is public (NASDAQ: IRON).
| Headquarters | Watertown, MA |
| Website | www.discmedicine.com |
| @discmedicine | |
| Pipeline Status | Clinical |